FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/03/024120 [Registered on: 20/03/2020] Trial Registered Prospectively
Last Modified On: 27/02/2020
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   To Compare the efficacy of Dhatri Loha with tablet Ferrous Sulphate in Pandu (Anaemia) 
Scientific Title of Study   A RANDOMIZED CONTROLLED CLINICAL TRIAL TO COMPARE THE EFFICACY OF DHATRI LOHA WITH TABLET FERROUS SULPHATE IN PANDU 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Kashmira Vishnu Raikar 
Designation  PG student 
Affiliation  PDEAs college of Ayurved and Research Centre,Akurdi. 
Address  PDEAs college of Ayurved and Research Centre Akurdi sect 25,3rd floor, Kaychikitsa department, opd no 117, Ayurved Rugnalay Sterling Multispeciality Hospital Nigdi Pune 411044

Pune
MAHARASHTRA
411044
India 
Phone  8796558521  
Fax    
Email  kashmiraraikar@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Medha Mahesh Joshi 
Designation  HOD and Guide Department of Kaychikitsa 
Affiliation  PDEAs college of Ayurved and Research Centre,Akurdi. 
Address  PDEAs college of Ayurved and Research Centre Akurdi sect 25 Ayurved Rugnalay Sterling Multispeciality Hospital Nigdi Pune 411044

Pune
MAHARASHTRA
411044
India 
Phone  9881465798  
Fax    
Email  medhamaheshjoshi@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Kashmira Vishnu Raikar 
Designation  PG student 
Affiliation  PDEAs college of Ayurved and Research Centre,Akurdi. 
Address  PDEAs college of Ayurved and Research Centre Akurdi sect 25, 3rd floor, Kaychikitsa department, opd no 117, Ayurved Rugnalay Sterling Multispeciality Hospital Nigdi Pune 411044

Pune
MAHARASHTRA
411044
India 
Phone  8796558521  
Fax    
Email  kashmiraraikar@gmail.com  
 
Source of Monetary or Material Support  
PDEAs college of Ayurved and Research Centre Nigdi Pune 411044 
 
Primary Sponsor  
Name  PDEAs college of Ayurved and Research Centre Nigdi Pune 
Address  PDEAs college of Ayurved and Research Centre Akurdi sect 25 Nigdi Pune 411044 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Kashmira Vishnu Raikar  PDAyurved Rugnalay Sterling Multispeciality Hospital Nigdi Pune   Ayurved Rugnalay Sterling Multispeciality Hospital sec 27,3rd floor, Kaychikitsa department, room no 32, Nigdi Pradhikaran Pune 411044
Pune
MAHARASHTRA 
8796558521

kashmiraraikar@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethical Committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: D50-D89||Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Dhatri Loha 500mg  Dhatri Loha is prepared as per Ayurverd Text.Dose 500mg twice a day for two months.Route Oral 
Comparator Agent  Tablet ferrous sulphate   Tablet ferrous sulphate 200mg once a day for two months Route Oral 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  patients having following symptoms
Panduta, Ayasenshwas, akshikootshotha, agnimandya, bhrama 
 
ExclusionCriteria 
Details  1 Anaemia associated with major systemic diseases like CCF, TB, CANCER, HIV,
2 Pregnant women, Lactating mothers
3 Mrudbhakshanjanya Pandu
4 Patient suffering from other types of anaemia like thalassemia, sickle cell anaemia  
 
Method of Generating Random Sequence   Coin toss, Lottery, toss of dice, shuffling cards etc 
Method of Concealment   Alternation 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
to compare the efficacy of Dhatri Loha 500mg twice a day with tablet ferrous sulphate 200mg once a day within 8 weaks.   60 days with follow up on 15th, 30th, 45th and 60th day. 
 
Secondary Outcome  
Outcome  TimePoints 
1 To study the efficacy of Dhatri Loha
2 To compare efficacy of Dhatri loha with tablet ferrous sulphate
3 To study adverse effect if any 
60 days OR 8 Weaks with follow up on 15th, 30th, 45th and 60th day. 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 1/ Phase 2 
Date of First Enrollment (India)   25/03/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   None yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary   India is a developing country, it has relatively bigger number of health issues and malnutrition due to poverty, illiteracy or lack of heath services. Now a days anaemia is major problem in India and it affects approximately one third of the population. In modern science, anaemia means lower concentration of haemoglobin in blood. Multiple modern drugs are available but they gives some side effects also. Dietary modification is used as treatment but effective in very few patients. There is no work done on Dhatri loham and tablet Ferrous sulphate in Pandu, so these drugs and disease combination is selected. 
Close